Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda symbols : VTRS save search
Viatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl™ (Phentolamine Ophthalmic Solution)
Published: 2023-09-27 (Crawled : 13:00) - biospace.com/
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: 0.0%
H: 1.03%
C: -1.34%
OCUP | $1.66 -0.6% -0.6% 230K
|
Health Technology
|
| O: 0.75%
H: 3.46%
C: -6.67%
fda pharma approval ryzumvl
Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents
Published: 2023-09-27 (Crawled : 12:00) - globenewswire.com
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: 0.0%
H: 1.03%
C: -1.34%
OCUP | $1.66 -0.6% -0.6% 230K
|
Health Technology
|
| O: 0.75%
H: 3.46%
C: -6.67%
fda pharma approval treatment eye ryzumvl
Viatris Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), a Once-daily Treatment for Children Living with HIV
Published: 2023-09-05 (Crawled : 09:00) - prnewswire.com
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: 0.0%
H: 0.88%
C: -1.58%
fda tentative children approval treatment hiv living
U.S. FDA Approves First Therapeutic Indication for Revance’s DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
Published: 2023-08-14 (Crawled : 13:00) - biospace.com/
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: -1.06%
RVNC | $3.77 -0.53% -0.53% 1.6M
|
Health Technology
|
| O: 6.13%
H: 1.54%
C: -3.04%
daxxify fda treatment injection
Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis
Published: 2023-08-07 (Crawled : 12:00) - biospace.com/
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: 2.46%
H: 5.81%
C: 1.38%
fda pharma drug sclerosis treatment application
Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol® Eye Drops for Reversal of Mydriasis
Published: 2022-12-06 (Crawled : 15:00) - biospace.com/
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -0.18%
H: 0.92%
C: 0.28%
OCUP | $1.66 -0.6% -0.6% 230K
|
Health Technology
|
| O: 0.93%
H: 4.0%
C: -6.15%
nyxol fda pharma drug eye application submission
Revance Announces FDA Approval of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection, the First and Only Peptide-Formulated Neuromodulator With Long-Lasting Results
Published: 2022-09-08 (Crawled : 18:00) - biospace.com/
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -0.57%
H: 0.83%
C: 0.16%
RVNC | $3.77 -0.53% -0.53% 1.6M
|
Health Technology
|
| O: 18.79%
H: 3.03%
C: 2.35%
fda approval
Viatris Inc. Announces Receipt of the First FDA Approval for Generic Version of Symbicort® Inhalation Aerosol, Breyna™ (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol), in Partnership with Kindeva
Published: 2022-03-16 (Crawled : 12:00) - prnewswire.com
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: 1.46%
H: 3.86%
C: 2.82%
symbicort fda partnership fda approval approval
Viatris is First to Receive FDA Approval of Generic Restasis® (Cyclosporine Ophthalmic Emulsion 0.05%) to Treat Dry Eye Disease
Published: 2022-02-03 (Crawled : 23:00) - prnewswire.com
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -1.05%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -2.48%
H: 0.0%
C: 0.0%
restasis dry eye fda eye fda approval eye disease approval disease ophthalmic emulsion
Viatris Inc. and Kindeva Drug Delivery Announce FDA Tentative Approval of the First Abbreviated New Drug Application Generic Version of Symbicort® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol
Published: 2021-03-08 (Crawled : 12:10) - prnewswire.com
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -1.08%
H: 2.11%
C: 0.51%
new drug fda drug drug delivery liver approval
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.